Glaucomatous neurodegeneration: an eye on tumor necrosis factor-alpha

Indian J Ophthalmol. 2012 Jul;60(4):255-61. doi: 10.4103/0301-4738.98700.

Abstract

Glaucoma, a neurodegenerative disease, is currently being treated by modulation of one of its primary risk factors, the elevated intraocular pressure. Newer therapies that can provide direct neuroprotection to retinal ganglion cells are being extensively investigated. Tumor necrosis factor-α, a cytokine, has been recognized to play an important role in pro and antiapoptotic cellular events. In this paper we review the relevant literature to understand (1) The association of increased expression of tumor necrosis factor-α with glaucomatous neurodegeneraion, (2) Modulation of tumor necrosis factor-α expression by exposure to various risk factors of glaucoma, (3) Downstream cellular signaling mechanisms following interaction of tumor necrosis factor-α with its receptors and (4) Role of tumor necrosis factor-α as a possible target for therapeutic intervention in glaucoma. Literature was reviewed using PubMed search engine with relevant key words and a total of 82 English language papers published from 1990 to 2010 are included in this review.

Publication types

  • Review

MeSH terms

  • Apoptosis
  • Disease Progression
  • Glaucoma / complications*
  • Glaucoma / metabolism
  • Glaucoma / pathology
  • Humans
  • Optic Nerve Diseases / etiology*
  • Optic Nerve Diseases / metabolism
  • Optic Nerve Diseases / pathology
  • Retinal Ganglion Cells / metabolism
  • Retinal Ganglion Cells / pathology*
  • Tumor Necrosis Factor-alpha / biosynthesis*

Substances

  • Tumor Necrosis Factor-alpha